Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybeno[c]phenanthridinium hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines

British Journal of Cancer

Volumn 76, Issue 5, 1997, Pages 571-581

  Kanzawa, F ^a   Nishio, K ^a   Ishida, T ^a   Fukuda, M ^a   Kurokawa, H ^a   Fukumoto, H ^a   Nomoto, Y ^a   Fukuoka, K ^a   Bojanowski, K ^a   Saijo, N ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Anti tumour drug; Benzo c phenanthridine; NK109; Non cross resistance; Topo II inhibitor

Indexed keywords

7 HYDROXY 8 METHOXY 5 METHYL 2,3 METHYLENEDIOXYBENZO[C]PHENANTHRIDINIUM HYDROGEN SULFATE; ANTINEOPLASTIC AGENT; BENZO[C]PHENANTHRIDINE DERIVATIVE; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; GYRASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG ACCUMULATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TRANSPORT; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SCID MOUSE; TUMOR CELL LINE;

EID: 8544226920     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.428     Document Type: Article

References (42)

1. Akiyama S. Cornwell MM, Kuwano M, Pastan I and Gottesman MM (1988) Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling ot P-glycoprotein by a vinblastine analog. Mol Pharmacol 33: 144-147
2. Barret Y and Sauvaire Y (1992) Fagaronine, a novel antileukemic alkaloid. Phytother Res 6: 59-63
3. Bruggemann EP, Germann UA. Gottesman MM and Pastan I (1989) Two different regions of P-glycoprotein [corrected] are photoaffinity-labeled by azidopine [published erratum appear in J Biol Chem 1990. 265: 4172]. J Biol Chem 264: 15483-15488
4. Cowan KH, Batist G, Tulpule A, Sinha BK and Myers CE (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83: 9328-9332
5. Dano K (1973) Active outward transport ot daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Res Acta 323: 466-483
6. Deffie AM, Batra JK and Goldenberg GJ (1989) Direct correlanon between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 49: 58-62
7. Fojo A, Akiyama S. Gottesman MM and Pastan I (1985) Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 45: 3002-3007
8. Fukuda M. Inomata M, Nishio K, Fukuoka K, Kanzawa F, Arioka H, Ishida T, Fukumoto H, Kurokawa H, Oka M and Saijo N (1996) A topoisomerase II inhibitor, NK109, induces DNA single- and double-strand breaks and apoptosis Jap J Cancer Res 87: 1086-1091
9. Gottesman MM and Pastan I (1988) The multidrug transporter, a double-edged sword (Review). J Biol Chem 263: 12163-12166
10. Hanaoka M, Yamagishi H and Murai C (1985) Synthesis of fagaridine, a phenolic benzo[c]phenanthridine alkaloid. Chem Pharm Bull 33: 1763-1765
11. Hong WS, Saijo N, Sasaki Y, Minato K. Nakano H, Nakagawa K, Fujiwara Y, Nomura K andTwentyman PR (1988) Establishment and characterization of cisplatin- resistant sublines ol human lung cancer cell lines. Int J Cancer 41: 462-167
12. Horichi N, Tapiero H, Sugimoto Y, Bungo M, Nishiyama M, Fourcade A, Lampidis TJ, Kasahara K, Sasaki Y, Takahashi T and Saijo N (1990) 3′-Deamino-3′- morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res 50: 4698-4701
13. Ishikawa T and Ali-Osman F (1993) Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268: 201 16-20125
14. Kabasawa T, Kobayashi F, Ekimoto H, Suzuki M and Hanaoka M (1996) A novel benzo[c]phenanthridine derivative, NK109, is a highly active anticancer agent and DNA topoisomerase II inhibitor. Proc Am Assoc Cancer Res 37: 427
15. Kanzawa F, Hoshi A, Kuretani K, Saneyoshi M and Kawaguehi T (1981) Antitumor activity of 3′,5′-diesters of 5-fluoro-2′-deoxyuridine against murinc leukemia L 1210 cells. Cancer Chemother Phamacol 6; 19-23
16. Kanzawa F Maeda M, Sasaki T, Hoshi A and Kuretani K (1982) Murine lymphoma L5I 78Y cells resistant to purine antagonists: differences in cross-resistance to thioguanine-platinum(II) and selenoguatnine-platinum(II). J Natl Cancer lnst 68: 287-291
17. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nukagawa K, Fujiwara Y, Liu LF and Saijo N (1990) Establishment of a camptothecin analogue (CPT- 11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919-5924
18. Kanzawa F, Nishio K, Kubota N and Saijo N (1995) Antitumor activities of a new indolocarbazole substance. NB-506, and establishment of NB-506-resistant cell lines. SBC-3/NB. Cancer Res 55: 2806-2813
19. Kaufmann SH ( 1989) Induction of endonucleolytic DNA cleavage in human acute myelogcnous leukemia cells by etoposide, camptothecin, and cytotoxic anticancer drugs: a cautionary note. Cancer Res 49: 5870-5878
20. KessarSV, Gupta YP, Balakrishnan P, Sawal KK, Mohammad T and Dutt M (1988) Benzyne cyclization route to benzo[c]phenanthridine alkaloids. Synthesis of chelerythrine, decarine, and nilidine. J Org Chem 53, 1708-1713
21. Kimura I, Ohnoshi T, Hiraki S and Miyamoto H (1987) Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance. Jpn J Cancer Chemother 14: 830-836
22. Kondo H, Kanzawa F, Nishio K, Saito S and Saijo N (1994) In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines. Jpn J Cancer Res 85: 1050-1056
23. Kubota N, Nishio K, Takeda Y, Ohmori T. Funayatma Y, Ogasawara H, Ohira T, Kunikane H, Terashima Y and Saijo N (1994) Characterization of an etoposide-resistant human ovarian cancer cell line. Cancer Chemother Pharmacol 34: 183-190
24. Larsen AK, Grondard L, Couprie J, Desoize B, Comoe L, Jardillier JC and Riou JF (1993) The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol 46: 1403-1412
25. Liu LF and Miller KG (1981) Eukaryotic DNA topoiisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci USA 78: 3487-3491
26. Liu LF, Rowe TC, Yang L, Tewey KM and Chen GL ( 1983) Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem 258: 15365-15370
27. Marini JC, Miller KG and Englund PT (1980) Decatenation ol kineloplast DNA by topoisomerases. J Biol Chem 255: 4976-4979
28. Minato K. Kanzawa F, Nishio K, Nakagawa K, Fujiwara Y and Saijo N (1990) Characterization of an ctoposide-resistant human small-cell lung cancer cell line. Cancer Chemother Pharmacol 26: 313-317
29. Nelson EM, Tewey KM and Liu LF (1984) Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9- acridinylaminol-methanesulfon-m-aniside. Proc Natl Acad Sci USA 81: 1361-1365
30. Nishio K, Sugimoto Y, Nakagawa K, Niimi S, Fujiwara Y, Bungo M, Kasahara K, Fujiki H and Saijo N (1990) Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin. Br J Cancer 62: 415-419
31. Ohmori T, Morikage T, Sugimoto Y, Fujiwara Y, Kasahara K, Nishio K, Ohta S, Sasaki Y, Takahashi T and Saijo N (1993 ) The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC- 14/CDDP). Jpn J Cancer Res 84: 83-92
32. Ross W, RoweT, Glisson B, Yalowich J and Liu LF (1984) Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857-5860
33. Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL and Felsted RL (1987) Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884-7888
34. Skovsgaard T (1978) Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res 38: 1785-1791
35. Tewey KM, Chen GL, Nelson EM and Liu LF (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182-9187
36. Totlo FG and Mensah IA (1973) Fagaridine: a phenolic benzophenanthridine alkaloid from Fagara xanthoxyloides. Phytochemistry 12: 2315-2317
37. Tse YC, Kirkegaard K and Wang JC (1980) Covalent bounds between protein and DNA, J Biol Chem 255: 5560-5565
38. Tsuruo T, lida, HS, Kawabata H, Oh-Hata T, Hamada H and Utakoji T (1986) Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77: 682-692
39. Wang JC (1985) DNA topoisomerases, Annu Rev Biochem 54: 665-697
40. Wang LK, Johnson RK and Hecht CM ( 1993) Inhibition of topoisomerase I function by nitidine and fagaronine. Chem Res Toxocol 6: 813-818
41. Yang CP. Mellado W and Horwitz SB ( 1988) Azidopine photoaffinity labeling of multidrug resistance-associated glycoproteins. Biochem Pharmacol 37: 1417-1421
42. Yoshida M, Feng W, Saijo N and Ikekawa T (1996) Antitumor activity of daphnane- type diterpene gnidimacrin isolated from stellera cheamaejasme L. Int J Cancer 66:268-273